Anne M Muehe1, Ketan Yerneni1, Ashok J Theruvath1,2, Avnesh S Thakor1, Allison Pribnow3, Raffi Avedian4, Robert Steffner4, Jarrett Rosenberg1, Kristina E Hawk1, Heike E Daldrup-Link5,6. 1. Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA. 2. Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. 3. Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA, USA. 4. Department of Orthopedic Surgery, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA. 5. Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA. heiked@stanford.edu. 6. Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA, USA. heiked@stanford.edu.
Abstract
PURPOSE: Tumor response assessments on positron emission tomography (PET)/magnetic resonance imaging (MRI) scans require correct quantification of radiotracer uptake in tumors and normal organs. Historically, MRI scans have been enhanced with gadolinium (Gd)-based contrast agents, which are now controversial due to brain deposition. Recently, ferumoxytol nanoparticles have been identified as an alternative to Gd-based contrast agents because they provide strong tissue enhancement on MR images but are not deposited in the brain. However, it is not known if the strong T1- and T2-contrast obtained with iron oxide nanoparticles such as ferumoxytol could affect MR-based attenuation correction of PET data. The purpose of our study was to investigate if ferumoxytol administration prior to a 2-deoxy-2-[18F]fluoro-D-glucose [18F]FDG PET/MR scan would change standardized uptake values (SUV) of normal organs. PROCEDURES: Thirty pediatric patients (6-18 years) with malignant tumors underwent [18F]FDG-PET/MR scans (dose 3 MBq/kg). Fifteen patients received an intravenous ferumoxytol injection (5 mg Fe/kg) prior to the [18F]FDG-PET/MR scans (group 1). Fifteen additional age- and sex-matched patients received unenhanced [18F]FDG-PET/MR scans (group 2). For attenuation correction of PET data, we used a Dixon-based gradient echo sequence (TR 4.2 ms, TE 1.1, 2.3 ms, FA 5), which accounted for soft tissue, lung, fat, and background air. We used a mixed linear effects model to compare the tissue MRI enhancement, quantified as the signal-to-noise ratio (SNR), as well as tissue radiotracer signal, quantified as SUVmean and SUVmax, between group 1 and group 2. Alpha was assumed at 0.05. RESULTS: The MRI enhancement of the blood and solid extra-cerebral organs, quantified as SNR, was significantly higher on ferumoxytol-enhanced MRI scans compared to unenhanced scans (p < 0.001). However, SUVmean and SUVmax values, corrected based on the patients' body weight or body surface area, were not significantly different between the two groups (p > 0.05). CONCLUSION: Ferumoxytol administration prior to a [18F]FDG PET/MR scan did not change standardized uptake values (SUV) of solid extra-cerebral organs. This is important, because it allows injection of ferumoxytol contrast prior to a PET/MRI procedure and, thereby, significantly accelerates image acquisition times.
PURPOSE:Tumor response assessments on positron emission tomography (PET)/magnetic resonance imaging (MRI) scans require correct quantification of radiotracer uptake in tumors and normal organs. Historically, MRI scans have been enhanced with gadolinium (Gd)-based contrast agents, which are now controversial due to brain deposition. Recently, ferumoxytol nanoparticles have been identified as an alternative to Gd-based contrast agents because they provide strong tissue enhancement on MR images but are not deposited in the brain. However, it is not known if the strong T1- and T2-contrast obtained with iron oxide nanoparticles such as ferumoxytol could affect MR-based attenuation correction of PET data. The purpose of our study was to investigate if ferumoxytol administration prior to a 2-deoxy-2-[18F]fluoro-D-glucose [18F]FDG PET/MR scan would change standardized uptake values (SUV) of normal organs. PROCEDURES: Thirty pediatric patients (6-18 years) with malignant tumors underwent [18F]FDG-PET/MR scans (dose 3 MBq/kg). Fifteen patients received an intravenous ferumoxytol injection (5 mg Fe/kg) prior to the [18F]FDG-PET/MR scans (group 1). Fifteen additional age- and sex-matched patients received unenhanced [18F]FDG-PET/MR scans (group 2). For attenuation correction of PET data, we used a Dixon-based gradient echo sequence (TR 4.2 ms, TE 1.1, 2.3 ms, FA 5), which accounted for soft tissue, lung, fat, and background air. We used a mixed linear effects model to compare the tissue MRI enhancement, quantified as the signal-to-noise ratio (SNR), as well as tissue radiotracer signal, quantified as SUVmean and SUVmax, between group 1 and group 2. Alpha was assumed at 0.05. RESULTS: The MRI enhancement of the blood and solid extra-cerebral organs, quantified as SNR, was significantly higher on ferumoxytol-enhanced MRI scans compared to unenhanced scans (p < 0.001). However, SUVmean and SUVmax values, corrected based on the patients' body weight or body surface area, were not significantly different between the two groups (p > 0.05). CONCLUSION:Ferumoxytol administration prior to a [18F]FDG PET/MR scan did not change standardized uptake values (SUV) of solid extra-cerebral organs. This is important, because it allows injection of ferumoxytol contrast prior to a PET/MRI procedure and, thereby, significantly accelerates image acquisition times.
Entities:
Keywords:
Cancer imaging; Iron oxide nanoparticles; PET/MR imaging; Pediatric Cancer; Standardized uptake values
Authors: James C Davis; Najat C Daw; Fariba Navid; Catherine A Billups; Jianrong Wu; Armita Bahrami; Jesse J Jenkins; Scott E Snyder; Wilburn E Reddick; Victor M Santana; M Beth McCarville; Junyu Guo; Barry L Shulkin Journal: J Nucl Med Date: 2017-06-13 Impact factor: 10.057
Authors: Csanad G Varallyay; Eric Nesbit; Rongwei Fu; Seymur Gahramanov; Brendan Moloney; Eric Earl; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2013-03-13 Impact factor: 6.200
Authors: John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Axel Martinez-Möller; Michael Souvatzoglou; Gaspar Delso; Ralph A Bundschuh; Christophe Chefd'hotel; Sibylle I Ziegler; Nassir Navab; Markus Schwaiger; Stephan G Nekolla Journal: J Nucl Med Date: 2009-03-16 Impact factor: 10.057
Authors: Ashok J Theruvath; Florian Siedek; Anne M Muehe; Jordi Garcia-Diaz; Julian Kirchner; Ole Martin; Michael P Link; Sheri Spunt; Allison Pribnow; Jarrett Rosenberg; Ken Herrmann; Sergios Gatidis; Jürgen F Schäfer; Michael Moseley; Lale Umutlu; Heike E Daldrup-Link Journal: Radiology Date: 2020-05-05 Impact factor: 11.105